Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for Inflammatory Diseases
DT-9046 is a highly differentiated first-in-class biased negative allosteric modulator of PAR2 with game changing potential across multiple inflammatory diseases
Unique mechanism of action with potential to directly impact inflammation, tissue damage, and pain
Strasbourg, France – Montreal, Canada – Boston, United States, March 20, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces it has nominated and is progressing DT-9046, a candidate with game-changing potential in multiple inflammatory disease markets, including atopic dermatitis (AD), inflammatory bowel disease (IBD), arthritis but also neuroinflammation including migraine.
